Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Akash Kulgod shared that Dognosis gathered 10,000 patient samples in two years while remaining seed funded by operating in India. Taking advantage of strong local medical infrastructure and dollar-to-rupee cost arbitrage allowed the company to run massive, diverse clinical trials far cheaper and faster than in the United States.

Related Insights

While many US biotech companies feel trapped within the FDA regulatory framework, high-quality clinical ecosystems exist globally. If domestic regulatory authorities impose unreasonable requirements or spurious timeline delays, startups can conduct clinical trials in other rigorous jurisdictions. Australia, for instance, offers robust hospital infrastructure, precise diagnostic laboratories, and efficient regulatory oversight that can maintain high standards while sustaining trial momentum.

With a highly concentrated population, a single-payer system, and vast hospital capacity (90,000 beds in Seoul vs. 4,000 in Boston), South Korea offers a significant advantage for clinical development. This infrastructure allows trials to be completed 40% faster and at 40% lower cost compared to the US.

Biotech developers are migrating toward transnational development models that execute early clinical de-risking in regions like China, Australia, or the UK. This approach accelerates progression while maintaining strict data quality standards required by Western regulators for commercial approval.

US biotechs increasingly use sites like Australia to accelerate development, as Create Medicines did by moving from concept to clinic in under 12 months. What was once viewed with suspicion is now a key strategy to generate data faster and more cheaply, competing with the speed of China's ecosystem.

A treaty between the FDA and Brazil's health department allows clinical trials conducted in Brazil to be accepted by the FDA. This provides a pathway for biotech startups to drastically reduce R&D costs and accelerate timelines without compromising the "gold standard" of US regulatory approval.

Running diagnostic validation studies within regionally concentrated, demographically diverse populations produces clinical data accepted worldwide. Establishing research programs near major diverse population clusters enables startups to bypass the traditional prestige of life sciences hubs like the Golden Triangle.

For a smaller company, conducting a clinical trial within one country like the UK is highly efficient. It streamlines regulation under one agency (the MHRA), reduces costs, and allows for rapid patient enrollment by leveraging a tight-knit national network of clinical specialists.

China's ability to accelerate biotech development stems from faster patient recruitment for clinical trials. With a large, treatment-naive patient population willing to participate in studies, early-stage oncology trials can be completed in about half the time it takes in the US. This provides a significant strategic advantage for de-risking assets more quickly and cheaply.

Amidst growing uncertainty at the US FDA, biotech companies are using a specific de-risking strategy: conducting early-stage clinical trials in countries like South Korea and Australia. This global approach is not just about cost but a deliberate move to get fast, reliable early clinical data to offset domestic regulatory instability and gain a strategic advantage.

Sophia Genetics helped a hospital in India go from outsourcing tests to the US (with a 6-week delay) to performing them locally in under two weeks. This approach defines democratization not just as providing access, but as empowering local institutions to build their own knowledge and capabilities.